Mankind Pharma Ltd’s fundamental analysis highlights key financial metrics: Market Cap of ₹92,931.41 crore, PE Ratio of 48.58, Debt to Equity of 2.16 and Return on Equity of 22.24%. These indicators reflect the company’s financial health and market valuation.
Mankind Pharma Ltd Overview
Mankind Pharma Ltd is an Indian pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical formulations and consumer healthcare products. It operates in the pharmaceutical sector, focusing on various therapeutic areas and over-the-counter products.
The company is listed on both the NSE and BSE. With a market capitalization of ₹92,931.41 crore, it’s currently 7.35% away from its 52-week high and 37.82% away from its 52-week low.
Mankind Pharma Ltd Financial Results
Mankind Pharma Ltd reported strong financial performance in FY 24, with steady growth across revenue, profitability and balance sheet metrics. The company demonstrated a consistent upward trend in sales, profit and EPS, reinforcing its position in the healthcare sector.
1. Revenue Trend: The company’s revenue increased from ₹8,749 crores in FY 23 to ₹10,335 crores in FY 24, reflecting a healthy growth in sales.
2. Equity and Liabilities: Mankind Pharma Ltd’s equity capital remains steady at ₹40.06 crores, while total liabilities rose to ₹11,963 crores in FY 24, up from ₹9,715 crores in FY 23.
3. Profitability: Operating profit grew from ₹1,901 crores in FY 23 to ₹2,535 crores in FY 24, improving the operating margin from 21.41% to 23.88%.
4. Earnings per Share (EPS): EPS rose from ₹32 in FY 23 to ₹47.75 in FY 24, showing an improvement in shareholder earnings.
5. Return on Net Worth (RoNW): RoNW showed a positive trend with improved profitability and reserve growth, supported by higher net profits and consistent return on capital.
6. Financial Position: The company’s total assets increased to ₹11,963 crores in FY 24 from ₹9,715 crores in FY 23, indicating enhanced asset management and financial health.
Mankind Pharma Ltd Financial Analysis
| FY 24 | FY 23 | FY 22 | |
| Sales | 10,335 | 8,749 | 7,782 |
| Expenses | 7,800 | 6,849 | 5,792 |
| Operating Profit | 2,535 | 1,901 | 1,989 |
| OPM % | 23.88 | 21.41 | 24.94 |
| Other Income | 281 | 129 | 196 |
| EBITDA | 2,816 | 2,029 | 2,185 |
| Interest | 34 | 44 | 59 |
| Depreciation | 398 | 326 | 167 |
| Profit Before Tax | 2,384 | 1,659 | 1,960 |
| Tax % | 19 | 22 | 27 |
| Net Profit | 1,942 | 1,310 | 1,453 |
| EPS | 47.75 | 32 | 35.78 |
* Consolidated Figures in Rs. Crores
Mankind Pharma Limited Company Metrics
Mankind Pharma Ltd’s company metrics include a market capitalization of ₹92,931.41 crore, a book value per share of ₹240 and a face value of ₹1. With a debt-to-equity ratio of 2.16, a return on equity of 22.24% and no dividend yield, these figures underscore the company’s financial position and investment profile.
Market Capitalization: Market Capitalization represents the total market value of Mankind Pharma’s outstanding shares, amounting to ₹92,931.41 crore.
Book Value: The book value per share of Mankind Pharma is ₹240, indicating the value of the company’s net assets divided by its shares outstanding.
Face Value: The face value of Mankind Pharma’s shares is ₹1, which is the original cost of the shares as stated on the certificate.
Asset Turnover Ratio: The asset turnover ratio of 0.99 measures how efficiently Mankind Pharma uses its assets to generate revenue.
Total Debt: The total debt of ₹207.18 crore represents the sum of all short-term and long-term debt obligations of Mankind Pharma.
Return on Equity (ROE): The ROE of 22.24% measures Mankind Pharma’s profitability in generating income from its equity investments.
EBITDA (Q): The quarterly EBITDA of ₹786.27 crore represents Mankind Pharma’s earnings before interest, taxes, depreciation and amortization.
Mankind Pharma Ltd Stock Performance
Mankind Pharma Ltd delivered an impressive 1-year return on investment (ROI) of 38.1%, demonstrating strong performance for its investors. This consistent growth highlights the company’s ability to generate substantial returns over a short-term period, providing excellent value to shareholders.
| Period | Return on Investment (%) |
| 1 Year | 38.1 |
For example, if you had invested ₹1,000 in Mankind Pharma Ltd stock:
1 year ago, your investment would be worth ₹1,381.
Mankind Pharma Peer Comparison
Mankind Pharma Ltd stands out in comparison to pharmaceutical peers like Sun Pharma, Cipla and Dr Reddy’s Labs. While Sun Pharma leads with a market cap of ₹440,565.12 crores, Dr Reddy’s boasts a higher ROE of 21.39%. Zydus Lifesciences offers strong 1-year returns at 67.85%.
| Name | CMP Rs. | Mar Cap Rs.Cr. | P/E | ROE % | EPS 12M Rs. | 1Yr return % | ROCE % | Div Yld % |
| Sun Pharma.Inds. | 1836 | 440565.12 | 41.78 | 16.69 | 43.3 | 59.98 | 17.32 | 0.74 |
| Cipla | 1651.6 | 133429.64 | 30.09 | 16.79 | 53.3 | 33.13 | 22.8 | 0.79 |
| Dr Reddy’s Labs | 6567.8 | 109610.03 | 19.7 | 21.39 | 333.63 | 14.66 | 26.53 | 0.61 |
| Zydus Lifesci. | 1079.95 | 108726.97 | 26.08 | 20.67 | 41.57 | 67.85 | 22.34 | 0.28 |
| Lupin | 2224.95 | 101479.36 | 44.83 | 14.14 | 49.69 | 95.25 | 15.72 | 0.36 |
| Mankind Pharma | 2395.6 | 96056.55 | 51.24 | 19.71 | 48.12 | 38.12 | 24.57 | 0 |
| Aurobindo Pharma | 1539.15 | 90207.98 | 25.2 | 11.53 | 60.1 | 72.05 | 14.1 | 0.29 |
Mankind Pharma Shareholding Pattern
Mankind Pharma Ltd’s shareholding pattern as of June 2024 shows promoters holding 74.87%, a slight decrease from March 2024 at 74.88%. Foreign Institutional Investors (FII) increased their stake to 11.58%, while Domestic Institutional Investors (DII) hold 9.94%. Retail and others hold 3.61%.
| All values in % | Jun-24 | Mar-24 | Dec-23 |
| Promoters | 74.87 | 74.88 | 76.50 |
| FII | 11.58 | 9.87 | 6.74 |
| DII | 9.94 | 11.14 | 9.78 |
| Retail & others | 3.61 | 4.10 | 6.97 |
Mankind Pharma Ltd History
Mankind Pharma Limited is a prominent Indian pharmaceutical company specializing in the development, manufacture and marketing of diverse pharmaceutical formulations. The company’s product portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal and respiratory treatments, among others.
In addition to prescription drugs, Mankind Pharma has established a strong presence in the consumer healthcare segment. Its brand portfolio includes well-known names such as Manforce, Prega-News and Gas-O-Fast, demonstrating the company’s ability to cater to both medical and over-the-counter markets.
Mankind Pharma’s growth strategy has focused on expanding its product range and market reach. The company has consistently introduced new formulations and brands, while also strengthening its distribution network across India and in international markets.
How To Invest In Mankind Pharma Share?
To invest in Mankind Pharma shares, open a demat account with Alice Blue. Research the company’s fundamentals, financial performance and position in the pharmaceutical industry. Analyze historical stock data and compare it with industry peers.
Determine your investment strategy based on your financial goals and risk tolerance. Consider factors such as the company’s product portfolio, R&D pipeline and market expansion plans. Decide on the investment amount and timing.
Place your order through the broker’s platform. Regularly monitor your investment, staying updated on company news, quarterly results and pharmaceutical industry trends. Consider seeking advice from a financial advisor for personalized guidance and to ensure your investment aligns with your overall portfolio strategy.
Mankind Pharma Fundamental Analysis – FAQs
Mankind Pharma Ltd’s fundamental analysis reveals a Market Cap of ₹92,931.41 crore, PE Ratio of 48.58, Debt to Equity of 2.16 and Return on Equity of 22.24%. These metrics provide insights into the company’s financial health, profitability and market valuation.
Mankind Pharma’s market capitalization is ₹92,931.41 crore. This figure represents the total value of the company’s outstanding shares in the stock market, calculated by multiplying the current stock price by the number of outstanding shares.
Mankind Pharma Limited is an Indian pharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical formulations and consumer healthcare products. It specializes in various therapeutic areas and has a strong presence in both prescription drugs and over-the-counter products.
Mankind Pharma is owned by its founders, the Juneja family, along with other investors. As a publicly listed company, ownership is distributed among promoters, institutional investors and public shareholders through stock market participation.
The main shareholders of Mankind Pharma Ltd include the Juneja family as promoters, along with institutional investors and public shareholders. For the most current and accurate information on major shareholders, refer to the company’s latest shareholding pattern disclosure.
Mankind Pharma operates in the pharmaceutical industry. The company specializes in developing, manufacturing and marketing pharmaceutical formulations across various therapeutic areas, as well as consumer healthcare products, catering to both prescription and over-the-counter markets.
To invest in Mankind Pharma shares, open a demat account with Alice Blue. Research the company’s performance and pharmaceutical industry trends. Decide on your investment strategy. Place your order through the broker’s platform. Regularly monitor your investment, staying informed about market conditions. Consider seeking financial advice for personalized guidance.
Determining if Mankind Pharma is overvalued or undervalued requires analyzing its financials, growth prospects, industry position and peer comparison. Consider factors like PE ratio, future earnings potential and pharmaceutical industry trends. Consult recent analyst reports for expert opinions on the company’s valuation.
We hope you’re clear on the topic, but there’s more to explore in stocks, commodities, mutual funds, and related areas. Here are important topics to learn about.
Disclaimer: The above article is written for educational purposes and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
